Akums Drugs Gets 20-Year Patent for New GERD Treatment

Akums Drugs and Pharmaceuticals has made a major landmark by receiving a 20-year patent for its revolutionary 'tablet-in-tablet' technology aimed at treating Gastroesophageal Reflux Disease (GERD).

This innovative dual-layer formulation not only increases the drug's efficacy but also is designed to provide more targeted and prolonged relief to patients who suffer from chronic acid reflux and heartburn.

Besides the patent, the company has been granted permission by the Drug Controller General of India (DCGI) to introduce this advanced therapy in the local market. The combination of patent protection and regulatory clearance is a significant milestone in Akums’ innovation-driven growth strategy.

The patented acid-resistant, dual-release composition will probably lead to better patient outcomes as it guarantees controlled drug release and the absorption is enhanced thus, the problem of GERD for a long time will be addressed. As there are millions of people affected worldwide, this innovation becomes a possible game changer in the treatment of the widely spread condition.

Also Read: Roche Announces Promising Phase III Success for Gazyva in SLE

With 20 years of patent exclusivity as a backup, Akums is now in a very good position to consolidate its presence in the gastrointestinal therapeutics market. Industry insiders believe that this invention is a gateway to new business opportunities which could eventually place India at the forefront of pharmaceutical innovation.

On the path to market launch, the response of healthcare providers and patients, therefore, will be the real-world evidence of the effectiveness of this new approach which, among other things, through precision drug delivery and improved therapeutic efficacy, claims to revolutionize GERD care.